The next installment of CDC’s public health webinar series on bleeding disorders will showcase thalassemia as a case example in emerging approaches in gene therapy. The Food and Drug Administration approved the first gene therapy treatment in the United States for people with transfusion-dependent beta-thalassemia in August 2022.
In this presentation, speakers will review the status of the Food and Drug Administration-approved gene therapy process for thalassemia, discussing the science behind it, the results of the clinical trials associated with it and the clinical implications as gene therapy begins to be applied in a real-world setting. In addition, they will explore future clinical trials involving potential alternative gene therapy treatments.
The program is scheduled for 2-3 p.m. ET on Thursday, June 22. This webinar is free and open to public health professionals, clinicians and researchers seeking more information about thalassemia. Advanced registration is required.
